You just read:

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating JZP-258 for the Treatment of Idiopathic Hypersomnia

News provided by

Jazz Pharmaceuticals plc

Nov 29, 2018, 08:00 ET